Author Correction: TP53 loss creates therapeutic vulnerability in colorectal cancer

Yunhua Liu¹, Xinna Zhang^{2

3}, Cecil Han¹, Guohui Wan¹, Xingxu Huang⁴, Cristina Ivan^{2

3}, Dahai Jiang^{2

3}, Cristian Rodriguez-Aguayo^{3

5}, Gabriel Lopez-Berestein^{3

5}, Pulivarthi H Rao⁶, Dipen M Maru⁷, Andreas Pahl⁸, Xiaoming He⁹, Anil K Sood^{1

2

3}, Lee M Ellis¹⁰, Jan Anderl⁸, Xiongbin Lu^{11

12}

Affiliations

¹ Department of Cancer Biology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
² Department of Gynaecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, USA.
³ Center for RNA Interference and Non-coding RNAs, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
⁴ School of Life Science and Technology, ShanghaiTech University, Shanghai, China.
⁵ Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
⁶ Department of Paediatrics, Baylor College of Medicine, Houston, TX, USA.
⁷ Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
⁸ Heidelberg Pharma GmbH, Ladenburg, Germany.
⁹ Department of Biomedical Engineering, The Ohio State University, Columbus, OH, USA.
¹⁰ Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
¹¹ Department of Cancer Biology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. xiongbinlu@gmail.com.
¹² Center for RNA Interference and Non-coding RNAs, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. xiongbinlu@gmail.com.

Published Erratum

Yunhua Liu et al. Nature. 2021 Sep.

. 2021 Sep;597(7875):E6.

doi: 10.1038/s41586-021-03664-3.

¹ Department of Cancer Biology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
² Department of Gynaecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, USA.
³ Center for RNA Interference and Non-coding RNAs, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
⁴ School of Life Science and Technology, ShanghaiTech University, Shanghai, China.
⁵ Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
⁶ Department of Paediatrics, Baylor College of Medicine, Houston, TX, USA.
⁷ Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
⁸ Heidelberg Pharma GmbH, Ladenburg, Germany.
⁹ Department of Biomedical Engineering, The Ohio State University, Columbus, OH, USA.
¹⁰ Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
¹¹ Department of Cancer Biology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. xiongbinlu@gmail.com.
¹² Center for RNA Interference and Non-coding RNAs, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. xiongbinlu@gmail.com.

No abstract available

Erratum for

TP53 loss creates therapeutic vulnerability in colorectal cancer.
Liu Y, Zhang X, Han C, Wan G, Huang X, Ivan C, Jiang D, Rodriguez-Aguayo C, Lopez-Berestein G, Rao PH, Maru DM, Pahl A, He X, Sood AK, Ellis LM, Anderl J, Lu X. Liu Y, et al. Nature. 2015 Apr 30;520(7549):697-701. doi: 10.1038/nature14418. Epub 2015 Apr 22. Nature. 2015. PMID: 25901683 Free PMC article.